Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK

被引：9

作者：

Damm-Welk, Christine ^{[1
,2
]}

Siddiqi, Faraz ^{[3
]}

Fischer, Matthias ^{[4
,5
,6
]}

Hero, Barbara ^{[4
]}

Narayanan, Vignesh ^{[7
]}

Camidge, David Ross ^{[7
]}

Harris, Michael ^{[3
]}

Burke, Amos ^{[8
]}

Lehrnbecher, Thomas ^{[9
]}

Pulford, Karen ^{[10
]}

Oschlies, Ilske ^{[11
]}

Siebert, Reiner ^{[12
,13
]}

Turner, Suzanne ^{[3
]}

Woessmann, Wilhelm ^{[1
,2
]}

机构：

[1] Univ Giessen, NHL BFM Study Ctr, Giessen, Germany

[2] Univ Giessen, Dept Paediat Haematol & Oncol, Feulgenstr 12, D-35392 Giessen, Germany

[3] Univ Cambridge, Dept Pathol, Cambridge, England

[4] Univ Cologne, Dept Paediat Haematol & Oncol, Cologne, Germany

[5] Univ Cologne, Fac Med, Ctr Mol Med Cologne, Cologne, Germany

[6] Max Planck Inst Metab Res, Cologne, Germany

[7] Univ Colorado, Ctr Canc, Aurora, CO USA

[8] Addenbrookes Hosp, Dept Paediat Oncol, Cambridge, England

[9] Goethe Univ Frankfurt, Dept Paediat Haematol & Oncol, Frankfurt, Germany

[10] Univ Oxford, Nuffield Div Clin Lab Sci, Oxford, England

[11] Univ Kiel, Dept Pathol, Kiel, Germany

[12] Univ Kiel, Inst Human Genet, Campus Kiel, Kiel, Germany

[13] Univ Hosp Schleswig Holstein, Campus Kiel, Kiel, Germany

来源：

JOURNAL OF CANCER | 2016年 / 7卷 / 11期

基金：

英国惠康基金;

关键词：

ALK-antibody titre; NSCLC; neuroblastoma; lymphoma; ANAPLASTIC LYMPHOMA KINASE; LARGE-CELL LYMPHOMA; LUNG-CANCER; TYROSINE KINASE; NEUROBLASTOMA; GENE; FEATURES; DISEASE; ALCL; IDENTIFICATION;

D O I：

10.7150/jca.15238

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in other malignancies induces specific antibodies. Antibodies against ALK were detected in sera of one of 50 analysed ALK-expressing neuroblastoma patients, 13 of 21 ALK positive non-small cell lung carcinoma (NSCLC) patients, 13 of 22 ALK translocation-positive, but NPM-ALK-negative lymphoma patients and one of one ALK-positive rhabdomyosarcoma patient, but not in 20 healthy adults. These data suggest that boosting a pre-existent anti-ALK immune response may be more feasible for patients with ALK-positive NSCLC, lymphomas and rhabdomyosarcomas than for tumours expressing wild-type ALK.

引用

页码：1383 / 1387

页数：5

共 50 条

[1] NPM-ALK epitopes recognized by anti-ALK-antibodies in ALCL patients
Knoerr, F.
Weber, S.
Singh, V.
Woessmann, W.
Damm-Welk, C.
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 : 74 - 74
[2] Arsenic trioxide downregulates NPM-ALK and inhibits the proliferation of ALK-positive anaplastic large cell lymphoma
Piao, Wenying
Chau, David H. W.
Yue, Kevin L. M.
Kwong, Yok Lam
Tse, Eric W. C.
CANCER RESEARCH, 2015, 75
[3] Lymphomas expressing ALK fusion protein(s) other than NPM-ALK
Falini, B
Pulford, K
Pucciarini, A
Carbone, A
De Wolf-Peeters, C
Cordell, J
Fizzotti, M
Santucci, A
Pelicci, PG
Pileri, S
Campo, E
Ott, G
Delsol, G
Mason, DY
BLOOD, 1999, 94 (10) : 3509 - 3515
[4] ANTI-ALK ANTIBODIES IN CHILDREN WITH LYMPHOMA WITH VARIANT ALK TRANSLOCATIONS
Damm-Welk, C.
Oschlies, I.
Klapper, W.
Gesk, S.
Ait-Tahar, K.
Siebert, R.
Reiter, A.
Pulford, K.
Woessmann, W.
ANNALS OF ONCOLOGY, 2011, 22 : 113 - 114
[5] Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis
Mussolin, L.
Damm-Welk, C.
Pillon, M.
Zimmermann, M.
Franceschetto, G.
Pulford, K.
Reiter, A.
Rosolen, A.
Woessmann, W.
LEUKEMIA, 2013, 27 (02) : 416 - 422
[6] Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis
L Mussolin
C Damm-Welk
M Pillon
M Zimmermann
G Franceschetto
K Pulford
A Reiter
A Rosolen
W Woessmann
Leukemia, 2013, 27 : 416 - 422
[7] Prognostic significance of NPM-ALK fusion transcript overexpression in ALK-positive anaplastic large-cell lymphoma
Li, Chunmei
Takino, Hisashi
Eimoto, Tadaaki
Ishida, Takashi
Inagaki, Atsushi
Ueda, Ryuzo
Suzuki, Ritsuro
Yoshino, Tadashi
Nakagawa, Atsuko
Nakamura, Shigeo
Inagaki, Hiroshi
MODERN PATHOLOGY, 2007, 20 (06) : 648 - 655
[8] NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
Haque, Moinul
Li, Jing
Huang, Yung-Hsing
Almowaled, Meaad
Barger, Carter J.
Karpf, Adam R.
Wang, Peng
Chen, Will
Turner, Suzanne D.
Lai, Raymond
CANCERS, 2019, 11 (08)
[9] Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma
Redaelli, Sara
Ceccon, Monica
Pirola, Alessandra
Peronaci, Marco
Gambacorti-Passerini, Carlo
Mologni, Luca
BLOOD, 2015, 126 (23)
[10] Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
Redaelli, Sara
Ceccon, Monica
Antolini, Laura
Rigolio, Roberta
Pirola, Alessandra
Peronaci, Marco
Gambacorti-Passerini, Carlo
Mologni, Luca
ONCOTARGET, 2016, 7 (45) : 72886 - 72897

← 1 2 3 4 5 →